The overall objective of my research effort is to determine the origins of tumor cell heterogeneity in response to anti-cancer drugs, by coupling high-content analyses (dynamic live cell imaging, high-throughput assays) with theoretical and computational methods.
This is an attempt to address a deficiency in large-scale studies focusing on multiple genetic biomarkers that may be partially inadequate given the observed fractional killing of genetically-identical tumor cell populations after chemotherapeutic treatment. Ultimately this approach should serve to identify, on a tumor cell type basis, the most predictive set of biomarkers and design optimal therapeutic combinations.
|1. Thèses Inria-Inserm Médecine Numérique||150k€||2016-2019|
|2. Cancéropôle PACA, Single-cell Starting Package||5k€||2016|
|3. Cancéropôle PACA, Emergence Jeunes Chercheurs||30k€||2016|
|4. Marie Curie International Incoming Fellowship, EC FP7-PEOPLE, REA||270k€||2014-2016|
|5. Roche Sponsored Research Program at Harvard University||2x $25k||2012, 2013|
|6. European Respiratory Society, Lung Science Conference Award, Bursary recipient||1000€||2009|
|7. NIH T32 Training Grant (Department of Anesthesia), UCSF||$180k||2007-2010|
|8. Research Training Fellowship Award (American Lung Association of California)||$65k||2006-2007|
|9. Senior Research Training Fellowship (American Lung Association, National)||$105k||2005-2007|
|10. Cystic Fibrosis Research Inc., Junior investigator 12-month grant||3x $37k||2001, 2002, 2003|
|11. Polytech'Nice-Sophia, Pre-graduate mobility award||1000€||2000|
keywords: oncology, oncologie, lung, poumon, single cell, cancer, inflammation.